Expert perspectives on life sciences strategy, commercialization, and market dynamics.
Expert perspectives on life sciences strategy, commercialization, and market dynamics.
Market access has become one of the most critical determinants of a successful pharmaceutical launch in the United States. However, developing an effective market access strategy has grown significantly more complex over the past decade. Rising healthcare costs, gaps in coverage from traditional health plans, and margin pressures for manufacturers have accelerated complexity as well […]
Part 6 of 6 of The Policy-Driven PMA Pivot Series: While this series has examined the impact of individual policy changes, assessing them in isolation provides only a partial view. In practice, manufacturers will contend with the compounded effect of these policies, as their interdependencies and reinforcing dynamics collectively redefine the pricing and access landscape. […]
Part 5 of 6 of The Policy-Driven PMA Pivot Series: The combined forces of federal legislation (impacting all PBMs by requiring 100% rebate pass-through and flat-fee compensation structures), and the settlement outcomes of the FTC’s suit with Express Scripts, one of the largest PBMs (requiring a standard formulary offering that does not prioritize high list-price, […]
Part 4 of 6 of The Policy-Driven PMA Pivot Series: Alternative access models have begun to emerge to challenge the traditional PBM-rebate pricing structure that has historically governed how patients access medications in the US market. Whether in response to the shifting policy landscape or as an independent indicator that the GTN bubble was becoming […]
Part 3 of 6 of The Policy-Driven PMA Pivot Series: Months of anticipation following the current administration’s Most-Favored Nations (MFN) executive order and letters to 17 top pharmaceutical companies has culminated in the past quarter in three CMS reimbursement models – GLOBE (Part B FFS), GUARD (Part D), and GENEROUS (Medicaid). These current administration policies […]
Part 2 of 6 of The Policy-Driven PMA Pivot Series: Since its enactment in 2022 under the prior administration, key drug pricing provisions of the Inflation Reduction Act (IRA) have been fully implemented, including Part D Redesign in 2025 and the first 10 CMS-negotiated maximum fair prices (MFPs) for drugs in initial price applicability year […]
Part 1 of 6 of The Policy-Driven PMA Pivot Series: Market access has become one of the most critical determinants of a successful pharmaceutical launch in the United States. However, developing an effective market access strategy has grown significantly more complex over the past decade. Rising healthcare costs, gaps in coverage from traditional health plans, […]
DURHAM, NC— Triangle Insights Group by Valeris (Triangle), a premier strategy consulting firm that delivers high-impact solutions across the life sciences value chain, has announced the appointment of Erin Solano to Partner. Solano is a seasoned life sciences executive who possesses strong analytical and communication skills responsible for driving meaningful commercial success for her clients. […]